$3.41
3.13% yesterday
NYSE, Dec 26, 06:19 pm CET
ISIN
US05380C1027
Symbol
RCEL

AVITA Therapeutics Stock price

$3.52
-0.23 6.13% 1M
-1.42 28.74% 6M
-9.28 72.50% YTD
-9.39 72.73% 1Y
-3.24 47.93% 3Y
-15.43 81.42% 5Y
-3.33 48.61% 10Y
-21.48 85.92% 20Y
NYSE, Closing price Wed, Dec 24 2025
+0.08 2.33%
ISIN
US05380C1027
Symbol
RCEL
Industry

Key metrics

Basic
Market capitalization
$107.3m
Enterprise Value
$126.5m
Net debt
$19.1m
Cash
$23.3m
Shares outstanding
30.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.5 | 1.5
EV/Sales
1.8 | 1.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
5.6%
Return on Equity
-1,374.3%
ROCE
-2,179.6%
ROIC
-154.5%
Debt/Equity
-6.4
Financials (TTM | estimate)
Revenue
$72.4m | $72.7m
EBITDA
$-39.4m | $-41.3m
EBIT
$-41.4m | $-43.5m
Net Income
$-48.6m | $-45.9m
Free Cash Flow
$-37.1m
Growth (TTM | estimate)
Revenue
20.6% | 13.1%
EBITDA
31.6% | 24.7%
EBIT
29.1% | 22.2%
Net Income
15.3% | 25.8%
Free Cash Flow
37.7%
Margin (TTM | estimate)
Gross
84.8%
EBITDA
-54.4% | -56.8%
EBIT
-57.2%
Net
-67.1% | -63.2%
Free Cash Flow
-51.3%
More
EPS
$-1.7
FCF per Share
$-1.2
Short interest
10.0%
Employees
260
Rev per Employee
$250.0k
Show more

Is AVITA Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

AVITA Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a AVITA Therapeutics forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a AVITA Therapeutics forecast:

Buy
75%
Hold
25%

Financial data from AVITA Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
72 72
21% 21%
100%
- Direct Costs 11 11
35% 35%
15%
61 61
18% 18%
85%
- Selling and Administrative Expenses 83 83
6% 6%
114%
- Research and Development Expense 20 20
10% 10%
28%
-39 -39
32% 32%
-54%
- Depreciation and Amortization 2.06 2.06
129% 129%
3%
EBIT (Operating Income) EBIT -41 -41
29% 29%
-57%
Net Profit -49 -49
15% 15%
-67%

In millions USD.

Don't miss a Thing! We will send you all news about AVITA Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AVITA Therapeutics Stock News

Neutral
GlobeNewsWire
8 days ago
VALENCIA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Cary Vance, Chief Executive Officer, will present at the 44th Annual J.P.
Neutral
GlobeNewsWire
about one month ago
VALENCIA, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025, at 8:30 a.m.
Positive
24/7 Wall Street
about one month ago
The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA) blew out its fiscal third-quarter results and offered strong forward guidance, though perhaps not as robust as Wall Street had hoped.
More AVITA Therapeutics News

Company Profile

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

Head office United States
CEO James Corbett
Employees 260
Founded 1992
Website www.avitamedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today